SEC Form 4 · accession 0000899243-18-010320
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Samarth Kulkarni
Officer — Chief Executive Officer
Period of report
Apr 16, 2018
Accepted (ET)
Apr 18, 2018 · 4:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $19.12 | Apr 16, 2018 | A | 75,000 | D | — | Dec 1, 2027 | Common Shares | 75,000 | 150,000 | D |
Explanation of responses
- F1This performance-based option was granted on December 1, 2017 with respect to 75,000 Common Shares, with 75% of the shares vesting on December 1, 2020 and the remaining 25% of the shares vesting on December 1, 2021.